Abstract | BACKGROUND: OBJECTIVE: To evaluate the timing and effect of dupilumab on itch. METHODS: Analysis of data from 1505 patients with moderate to severe AD included in 4 randomized controlled studies, treated for up to 52 weeks. Adults received dupilumab 300 mg every 2 weeks or placebo monotherapy (SOLO 1: NCT02277743; SOLO 2: NCT02277769), with concomitant topical corticosteroids (CHRONOS: NCT02260986); adolescents (≥12 to <18 y) were treated with dupilumab monotherapy every 2 weeks (200 mg for baseline weight of <60 kg; 300 mg for baseline weight of ≥60 kg) or placebo (AD ADOL: NCT03054428). RESULTS:
Dupilumab showed significant rapid improvements from baseline in daily Peak Pruritus Numerical Rating Scale scores versus placebo, by day 2 in adults and day 5 in adolescents. At treatment end, dupilumab vs placebo/control had greater least-squares mean percent change from baseline in the weekly average of Peak Pruritus Numerical Rating Scale scores: SOLO -47.5% vs -20.5%; AD-ADOL -47.9% vs -19.0%; CHRONOS -57.3% vs -30.9% (P < .0001 for all). LIMITATIONS: Short duration of monotherapy trials (16 weeks). CONCLUSION: Across 4 randomized trials, dupilumab treatment showed rapid and sustained improvements in the magnitude of itch, starting with first dose; responses progressively increased and were sustained through to the end of treatment, up to 1 year.
|
Authors | Jonathan I Silverberg, Gil Yosipovitch, Eric L Simpson, Brian S Kim, Jashin J Wu, Laurent Eckert, Isabelle Guillemin, Zhen Chen, Marius Ardeleanu, Ashish Bansal, Mandeep Kaur, Ana B Rossi, Neil M H Graham, Naimish Patel, Abhijit Gadkari |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 82
Issue 6
Pg. 1328-1336
(Jun 2020)
ISSN: 1097-6787 [Electronic] United States |
PMID | 32135208
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Dermatologic Agents
- dupilumab
|
Topics |
- Adolescent
- Adult
- Antibodies, Monoclonal, Humanized
(administration & dosage, therapeutic use)
- Dermatitis, Atopic
(complications, drug therapy)
- Dermatologic Agents
(administration & dosage, therapeutic use)
- Double-Blind Method
- Drug Administration Schedule
- Humans
- Pruritus
(drug therapy, etiology)
- Severity of Illness Index
- Young Adult
|